Archive
529 articles, sorted by publication time.
Big Pharma’s move to bring an external platform into early-stage R&D suggests the focus of the cancer vaccine race is shifting from a single drug candidate toward a technology foundation that can repeatedly design, deliver, and validate antigens.
A clinical trial suggests that a brain cancer vaccine may offer more durable treatment hope; but before design details, patient scale, and complete data are made public, it looks more like an early signal worthy of serious scrutiny than an answer ready to rewrite treatment standards.
Idiopathic pulmonary fibrosis lacks therapies that can reverse the course of disease; a candidate drug designed with AI involvement has advanced into late-stage clinical development, moving algorithmic drug discovery from concept demonstration toward the rigorous test of patient outcomes.
Generative models can propose targets and molecules faster, but they cannot replace human trials. The next test for the AI drug development boom may not be who can design a candidate drug first, but who can build stronger clinical evidence.
As artificial intelligence expands from candidate molecule design to participant recruitment, trial monitoring, and data interpretation, the biomedical industry sees the possibility of shortening development timelines; but clinical trials pursue more than efficiency, requiring evidence that is traceable, verifiable, and trusted by regulators.
Argus raised its price target for IQVIA, showing that capital markets are extending the value of AI drug R&D from algorithm startups to the infrastructure for data, trials, and real-world evidence.
As new drug development moves toward higher costs, longer validation, and more complex supply chains, the agenda of this annual biotech conference in Taipei reflects how Asia’s industry is shifting from technology showcases toward clinical, manufacturing, and regulatory implementation.
For a rare and complex childhood disease such as congenital myotonic dystrophy, regulators’ agreement on how a trial should be conducted is often as critical as the drug itself. AMO Pharma’s latest progress suggests that AMO-02 is seeking to turn uncertain clinical development questions into an executable registration study design.
An active ingredient derived from the kratom plant but concentrated into gummies, drinks, and capsules is bringing pain, self-medication, and addiction policy to the same regulatory table.
The time physicians spend at the keyboard is becoming an entry point in the race for medical AI; Kiko is betting on automatically generated clinical records, but beyond promises of efficiency, accuracy, accountability, and patient privacy will determine whether it can truly enter the exam room.
The varicella vaccine is far from a new technology, but dosing, protection, and immunization policy continue to shape public health choices. GC Biopharma’s new trial will move its two-dose product into a clinical stage closer to a potential market decision.
This is not simply another anticancer drug that blocks signals, but one that hands a cancer-driving protein over to the cell’s clearance system. Its approval moves the PROTAC concept from laboratory terminology into a formal treatment option for some patients with advanced breast cancer.